Menu
X
doctor.wang@globecancer.com Become Our Partner Get Free Help

Leukemia

image
A CAR-T Success Story in China: A Beacon of Hope for Acute Myeloid Leukemia(AML) Patients

A CAR-T Success Story in China: A Beacon of Hope for Acute Myeloid Leukemia(AML) Patients #CAR-T #AcuteMyeloidLeukemia #AML #ChinaHealthcare #patientstory #CD33 In the field of cancer treatment, China’s medical advancements have brought new therapeutic opportunities for patients, especially with CAR-T cell therapy. Although CAR-T has achieved significant success in treating lymphoid tumors, its application in myeloid malignancies, particularly acute Read More

October 15th,2024 Leukemia
image
Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL

**Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL** #CAR-TTherapy #TALL #ALL #Leukemia #RelapsedLeukemia #TCellLeukemia #CD5 #CD7 #CART Recently, a collaborative research study conducted by multiple Chinese medical and research institutions was published in *Nature Medicine*. This study, titled “Allogeneic CD5-specific CAR-T Therapy for Relapsed/Refractory T-ALL: A Phase 1 Read More

October 12th,2024 Leukemia
image
Real-World Performance of China’s Anti-Cancer Drug Zanubrutinib in CLL/SLL Treatment: Efficacy and Safety

**Real-World Performance of China’s Anti-Cancer Drug Zanubrutinib in CLL/SLL Treatment: Efficacy and Safety** #Ibrutinib #Zanubrutinib #CLL #SLL #BTKinhibitor #Oncology #cancerdrug #BTK #ASCO With the advent of BTK inhibitors, the treatment paradigm for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has undergone a complete transformation, moving away from traditional chemotherapy. Zanubrutinib, a powerful BTK inhibitor developed independently Read More

September 9th,2024 Leukemia
image
Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment

Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment In the field of hematological malignancies, the treatment of acute myeloid leukemia (AML) has long been a challenge in the medical community. Particularly for relapsed or refractory patients, the limitations of traditional treatments have increased the urgent need for Read More

August 12th,2024 Leukemia
image
Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient

### Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient | Successful Case from The First Affiliated Hospital of Chongqing Medical University On November 7, 2023, China’s first CAR-T product for treating adult leukemia, Yuan Ruida (Inaticabtagene Autoleucel Injection), was officially approved for market release. This marks a significant breakthrough Read More

July 4th,2024 CAR-T , Leukemia
The new hope for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) boasts an overall survival rate of up to 96%.

The new hope for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) boasts an overall survival rate of up to 96%.     Recently, CAR-T cell therapy targeting B-cell malignancies has encountered a series of inquiries and challenges, particularly concerning discussions on CAR-T cell-related toxicity, resistance, antigen escape, and limitations in persistence. However, Read More

December 21st,2023 CAR-T , Leukemia
Recent Posts

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.